Skip to main content

Table 4 Quality of life, sleep quality, and physical activity. Baseline data and changes (%) in response to 12 months of treatment with melatonin or placebo. Median scores with 25–75 % interquartile range

From: The effect of melatonin treatment on postural stability, muscle strength, and quality of life and sleep in postmenopausal women: a randomized controlled trial

  Baseline P-value Changes after 12 months (%) P-value*
Physical component score   0.69   0.16
 Placebo 54.9 (48.2;56.9)   1.80 (−3.79;7.11)  
 Melatonin 54.7 (50.9;57.4)   −0.30 (−4.00;4.83)  
Mental component score   0.12   0.94
 Placebo 56.6 (51.8;59.0)   −0.78 (−5.88;4.47)  
 Melatonin 58.0 (55.6;59.5)   −0.34 (−6.13;4.12)  
WHO-5 Well-being Index   0.63   0.27
 Placebo 80.0 (72.0;84.0)   0.00 (−9.52;5.00)  
 Melatonin 80.0 (73.0;84.0)   0.00 (−5.00;5.56)  
Pittsburgh Sleep Quality Index   0.36   0.31
 Placebo 5.0 (2.0;8.5)   0.00 (−32.14;38.33)  
 Melatonin 4.5 (3.0;5.0)   0.00 (−41.11;28.79)  
Pittsburgh Sleep Quality Index > 5   0.47   0.08
 Placebo, N = 20 8.5 (6.0;9.8)   −13.3 (−32.1;9.4)  
 Meltonin, N = 9 8.0 (6.0;8.5)   −37.5 (−64.5;-15.5)  
Physical activity scalea   0.17   0.43
 Placebo 43.8 (37.4;48.7)   −0.16 (−8.46;8.29)  
 Melatonin 46.0 (40.9;51.3)   −2.27 (−13.84;10.07)  
  1. *Percentage change between groups
  2. aMetabolic equivalent (MET) score for 24 hours